Esperion Therapeutics (ESPR) Net Cash Flow Growth (1y) (2013 - 2026)
Esperion Therapeutics (ESPR) Net Cash Flow Growth (1y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.69 Bn | 87.82 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.84 Bn | 32.10 Bn | 1.97 Bn | 112.26% |
| 3 | Zoetis | 32.67 Bn | 30.73 Bn | 1.62 Bn | -44.11% |
| 4 | Takeda Pharmaceutical | 27.69 Bn | 23.63 Bn | 4.39 Bn | 209.30% |
| 5 | United Therapeutics | 23.12 Bn | 20.97 Bn | 648.10 Mn | -236.85% |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.24 Bn | 18.44 Bn | 1.16 Bn | 13,485.29% |
| 8 | Neurocrine Biosciences | 17.83 Bn | 16.51 Bn | 800.70 Mn | -1,047.81% |
| 9 | Elanco Animal Health | 12.64 Bn | 12.22 Bn | 785.00 Mn | -1,020.00% |
| 10 | Esperion Therapeutics | 799.30 Mn | 643.14 Mn | 45.53 Mn | 61.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 61.19% |
| Dec 31, 2025 | 171,275.00% |
| Sep 30, 2025 | 114.32% |
| Jun 30, 2025 | 23.41% |
| Mar 31, 2025 | -120.87% |
| Dec 31, 2024 | 100.14% |
| Sep 30, 2024 | -88.63% |
| Jun 30, 2024 | -479.18% |
| Mar 31, 2024 | 616.93% |
| Dec 31, 2023 | 61.49% |
| Sep 30, 2023 | -164.83% |
| Jun 30, 2023 | 76.51% |
| Mar 31, 2023 | 134.40% |
| Dec 31, 2022 | -180.43% |
| Sep 30, 2022 | 155.65% |
| Jun 30, 2022 | -2,299.20% |
| Mar 31, 2022 | 32.74% |
| Dec 31, 2021 | 17.94% |
| Sep 30, 2021 | 20.82% |
| Jun 30, 2021 | -99.16% |